The cost effectiveness of a randomized controlled trial to establish the relative efficacy of vitamin K1 compared with alendronate

Medical Decision Making

Volumn 31, Issue 1, 2011, Pages 43-52

  Stevenson, Matt D ^a   Jones, Myfanwy Lloyd ^a  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

Cost utility analysis; Cost effectiveness analysis; Decision analysis; Osteoporosis; Probabilistic sensitivity analysis; Value of information

Indexed keywords

ALENDRONIC ACID; ANTIFIBRINOLYTIC AGENT; BONE DENSITY CONSERVATION AGENT; PHYTOMENADIONE;

AGED; ARTICLE; COMPARATIVE STUDY; COST BENEFIT ANALYSIS; DECISION MAKING; ECONOMICS; FEMALE; HUMAN; OSTEOPOROSIS; QUALITY ADJUSTED LIFE YEAR; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK; RISK FACTOR; STATISTICAL MODEL; THEORETICAL MODEL; UNITED KINGDOM;

AGED; ALENDRONATE; ANTIFIBRINOLYTIC AGENTS; BONE DENSITY CONSERVATION AGENTS; COST-BENEFIT ANALYSIS; DECISION MAKING; ENGLAND; FEMALE; HUMANS; MODELS, ECONOMIC; MODELS, THEORETICAL; OSTEOPOROSIS; QUALITY-ADJUSTED LIFE YEARS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK; RISK FACTORS; VITAMIN K 1; WALES;

EID: 79953856885     PISSN: 0272989X     EISSN: 1552681X     Source Type: Journal    
DOI: 10.1177/0272989X10364848     Document Type: Article

References (22)

1. Consensus Development Conference. Diagnosis, prophylaxis and treatment of osteoporosis. Am J Med. 1991;90:107-10.
2. Kanis JA, Gluer CC. An update on the diagnosis and assessment of osteoporosis with densitometry. Osteoporos Int. 2000;11: 192-202. (Pubitemid 30216170)
3. Stevenson M, Davis S, Lloyd-Jones M, Beverley C. The clinical effectiveness and cost effectiveness of strontium ranelate for the prevention of osteoporotic fragility fractures in postmenopausal women. Health Technol Assess. 2007;11(4):1-134.
4. Osteoporosis Secondary Prevention Guidance. National Institute for Health and Clinical Excellence. Available from: URL: http://guidance.nice.org.uk/TA87.
5. National Institute for Health and Clinical Excellence. Osteoporosis - secondary prevention (final appraisal determination). Available from: URL: http://guidance.nice.org.uk/page.aspx?o=437523. Accessed August 2007.
6. Cheung AM, Tile L, Lee Y, et al. Vitamin K supplementation in postmenopausal women with osteopenia (ECKO trial): a randomized controlled trial. PLoS Med. 2008;5:e196.
7. Stevenson MD, Oakley JE, Lloyd Jones M, et al. The costeffectiveness of an RCT to establish whether 5 or 10 years of bisphosphonate treatment is the better duration for women with a prior fracture. Med Decis Making. 2009;29(6):678-89.
8. Stevenson MD, Brazier JE, Calvert NW, Lloyd-Jones M, Oakley J, Kanis JA. Description of an individual patient methodology for calculating the cost effectiveness of treatments for osteoporosis in women. J Oper Res Soc. 2005;56(2):214-21. (Pubitemid 40212817)
9. Stevenson M, Lloyd Jones M, Papaioannou D. Vitamin K to prevent fractures in older women: systematic review and economic evaluation. Health Technol Assess. 2009;13(45):iii-xi, 1-134.
10. Binkley NC, Suttie JW. Vitamin K nutrition and osteoporosis. J Nutr. 1995;125:1812-21.
11. National Institute for Clinical Excellence. Guide to the methods of technology appraisals. 2008. Available from: URL: http://www.nice.org.uk/media/ B52/A7/TAMethodsGuideUpdatedJune2008.pdf.
12. Kind P, Dolan P, Gudex C, Williams A. Variations in population health status: results from a United Kingdom national questionnaire survey. BMJ. 1998;316:736-41. (Pubitemid 28121072)
13. British Medical Association and Royal Pharmaceutical Society of Great Britain. British national formulary (BNF). No. 56, 2008. London: BMA and RPS; 2008.
14. Stevenson M, Davis S. Analyses of the cost effectiveness of pooled alendronate and risedronate, compared with strontium ranelate, raloxifene, etidronate and teriparatide. 2006. Available from: URL: http://www.nice.org.uk/ nicemedia/pdf/Osteoporosis-economic-DSU-2006-July.pdf.
15. Kanis JA, Johnell O, Oden A, et al. The risk and burden of vertebral fractures in Sweden. Osteoporos Int. 2004;15:20-6. (Pubitemid 38252435)
16. Todd CJ, Freeman C, Camilleri-Ferrante C. Anglian Audit of Hip Fracture 2. Cambridge (UK): Cambridge Health Services Research Group; 1999.
17. Kanis JA, Oden A, Johnell O, De Laet C, Jonsson B. Excess mortality after hospitalization for vertebral fracture. Osteoporos Int. 2004;15:108-12. (Pubitemid 38252423)
18. The Government Actuary Department. Interim life tables. England and Wales. Available from: URL: http://www.gad.gov.uk/Demography%20Data/ Life%20Tables/Interim-life-tables.html. Accessed May 2009.
19. Kanis JA, Brazier J, Stevenson M, Lloyd-Jones M, Calvert NW. Treatment of established osteoporosis. Health Technol Assess. 2002;6(29):1-146.
20. Ades AE, Lu G, Claxton K. Expected values of sample information calculation in medical decision making. Med Decis Making. 2004;24:207-27. (Pubitemid 38391940)
21. Brennan A, Kharroubi SA. Efficient computation of partial expected value of sample information using Bayesian approximation. J Health Econ. 2007;26:122-48. (Pubitemid 44908721)
22. Stinnett A, Mullahy J. Net health benefits: a new framework for the analysis of uncertainty in cost effectiveness analyses. Med Decis Making. 1998;18:S68-80. (Pubitemid 28175944)